Latest Breaking News On - Dave chenn - Page 1 : comparemela.com

Sanofi, Pfizer, Acelyrin and more—Chutes & Ladders

YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer

YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer

YS Biopharma To Hold Extraordinary General Meeting On May 21, 2024 And Announces The Appointment Of Interim Chief Executive Officer

Oceanpine Capital leads $73m funding in US biopharma firm Immune-Onc

Oceanpine Capital leads $73m funding in US biopharma firm Immune-Onc April 1, 2021 Immune-Onc Therapeutics, a California-based cancer immunotherapy firm co-founded by Chinese pharma specialist Charlene Liao, has raised $73 million in Series B1 and B2 rounds of financing, it announced earlier this week.   The latest funding brings the total capital raised by the company to $110 million, it said in a statement.  Beijing-headquartered Oceanpine Capital was the lead investor in the two rounds, which were joined by return backers Northern Light Venture Capital and Vivo Capital. Following the financing, Oceanpine CEO and managing partner Dave Chenn joined the Immune-Onc board of directors. The biopharma firm’s Series B1 and B2 rounds also attracted a slew of Chinese investors, including South China Venture Capital, Sherpa Healthcare Partners, BOCOM International Holdings, Triwise Capital, Qianzhan Investment, Yanchuang Capital, Tao Capital and Yinglian Healthcare Fund.